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Abstract  
Introduction: Different methods have been well addressed in literature in terms of treating superior vena 
cava (SVC) syndrome; nevertheless, the patency of endovascular treatment has rarely been investigated in 
patients with SVC syndrome in patients with central venous access.  
Objectives: The present study was performed to assess the patency rate of endovascular procedure in patients 
with SVC syndrome caused by intravenous catheterization. 
Methods: The present case series and longitudinal study was conducted on patients with SVC syndrome in 
presence of central venous catheter who underwent venoplasty. Computed tomography (CT) venography was 
performed 1, 6 and 12 months after venoplasty. Facial swelling, facial discomfort, extremity edema, 
arteriovenous fistula (AVF) dysfunction, impairment in dialysis and SVC stenosis were measured at baseline 
and 1, 6 and 12 months after venoplasty. 
Results: Out of 20 investigated patients, 11 (55%) were male. Significantly decreases were observed in the 
median grades of facial swelling and extremity edema in the follow-up (P<0.001). The decrease in facial 
discomfort was statistically insignificant (P=0.129), and the median grade of SVC stenosis significantly 
decreased from 1.5 to zero in the follow-up (P<0.001). A statistically-significant decrease was observed in AVF 
dysfunction (P=0.007), and impairment in dialysis significantly decreased after the intervention during the 
follow-up (P<0.001). 
Conclusion: Findings of the present study revealed the appropriate patency rate of endovascular treatment in 
patients with SVC syndrome in presence of central venous catheter. 
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INTRODUCTION
The symptoms of superior vena cava (SVC) 
syndrome include obstruction of the SVC vein and 
swelling of the head, face, neck, arms and breasts. 
SVC syndrome may also cause cyanosis, plethora 
and distended subcutaneous veins. With an 
approximate annual incidence of 15000 cases, this 
syndrome is considered a rare condition in the US 
(1-7). Although the majority of the cases are 
secondary to underling malignant diseases, 
especially lung cancer, the other causes reported to 
contribute to disruption to SVC flow include 
mediastinal fibrosis, pacemaker lead implantation 
and central venous catheterization insertion (8-
12). Different treatments proposed for SVC 
syndrome comprise percutaneous transluminal 
angioplasty, stent implantation, thrombolysis, 
mechanical thrombectomy and vein grafting (13-
21).  
Despite evaluating these methods in numerous 
studies, the patency rate of endovascular treatment 
has rarely been addressed in patients with SVC 
syndrome in presence of central venous access. The 
present study was performed to take a step 
towards improving the treatment of these patients.  
Methods 
Study design 
The present case-series and longitudinal study was 
performed on patients presenting in 2018-19 to 
Imam Khomeini Hospital in Tehran, Iran. The study 
protocol was approved by Ethics Committee of 
Tehran University of Medical Sciences, Tehran, 
Iran. The study included patients who signed 
informed consent forms. 
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Study population 
The eligible patients comprised those with SVC 
syndrome and AVF dysfunction (defined as high 
pressure of the venous structure or bleeding 
during dialysis or inappropriate dialysis as well as 
those with bleeding after dialysis catheter 
insertion, permcath malfunction). All the patients 
underwent venography; and venoplasty was 
performed in cases of occlusion and stenosis. The 
exclusion criteria comprised inability to follow up 
and SVC syndrome being caused by other 
conditions such as mediastinal fibrosis and lung 
cancer. 
Intervention and outcome assessment 
All the included patients who underwent 
venoplasty as a treatment for SVC syndrome were 
followed up by undergoing CT venography 1, 6 and 
12 months after the intervention. As a general term 
covering any pains felt in the mouth, jaws and the 
face, facial pain or facial discomfort was measured 
with a numerical rating pain Scale (NRPS), with a 
zero score denoting the absence of pain, 1-3 
represented as 1+, 4-6 as 2+ and 7-10 as 3+. 
Upper extremity edema defined as the 
accumulation of fluids causing swelling in tissues 
perfused by the peripheral vascular system was 
evaluated as follows: 
 Grade 0: Slight pitting, unnoticed changes in the 
extremity shape, a depth of indentation of 0-1/4” 
(<6 mm) and rapid disappearance of the 
symptoms  
 Grade 1: No marked changes in the extremity 
shape, a depth of indentation of 1/4 -1/2” (6-12 
mm) and disappearance in 10-15 seconds 
 Grade 2: Noticeably deep pitting, swollen 
extremity, a depth of pitting of 1/2-1” (1-2.5 cm) 
and a 1-2 minute duration of the symptoms  
 Grade 3: Very swollen and distorted extremity, a 
depth of pitting of over 1” (>2.5 cm) and a 2-5 
minute duration of the symptoms 
The narrowing or blockage of the SVC known as 
SVC obstruction was investigated using a five-point 
scale as follows: 
 Grade 0: SVC narrowing without clinical evidence 
of SVC syndrome 
 Grade 1: mild-to-moderate SVC narrowing 
without collaterals 
 Grade 2: severe SVC narrowing above the azygos 
vein serving as partial collateral 
 Grade 3: SVC obstruction below the azygos vein 
 Grade 4: SVC obstruction at the azygos arch 
In case of AVF dysfunction, the AVF flow was 
measured before and after the treatment using a 
Doppler ultrasound. The success criteria 
comprised improvements in the head and facial 
swelling, the AVF function and SVC vein stenosis 
after CT venography during the follow-up (21-24). 
Data collection 
The data were collected using a checklist consisting 
of demographic and baseline information about 
underlying diseases and symptoms. The 
demographic information comprised name, age, 
gender, the habitual history, including smoking, 
drug abuse and alcohol consumption, underlying 
diseases such as heart, pulmonary and kidney 
diseases and cancers and the symptoms before and 
after the treatment, i.e. facial and extremity 
swelling and facial discomfort. The patients 
completed the checklist in two stages, i.e. before 
and after the treatment, and the symptoms after 
the treatment were compared with those before 
the treatment to evaluate the patency. The clinical 
symptoms of the patients recorded by the 
researchers included the head and facial swelling, 
upper extremity edema, facial discomfort, fistula 
failure, dialysis disorder and SVC stenosis.  
Statistical analysis 
The data were analyzed in SPSS-22 using 
descriptive and analytical methods. The categorical 
variables were expressed as frequency and relative 
frequency and the numerical variables as 
mean±standard deviation (SD) and median with an 
interquartile range (IQR). The Chi-squared test was 
used to analyze the trend of distribution changes at 
four follow-up time points, i.e. baseline and three 
times after the intervention. The Friedman test was 
also used to numerically test the scores of the 
variables during the follow-up. Moreover, the 
Shapiro-Wilk test and graphical methods were 
used to investigate the distribution normality of 
the variables. P<0.05 was set as the level of 
statistical significance. 
RESULTS 
The present study investigated 11 (55%) males 
and 9 (45%) females. Permcath malfunction was 
observed in 11 (55%) cases, port dysfunction in 7 
(35%) and AVF dysfunction in 2 (10%). Clinical 
symptoms at baseline and follow-up in the patients 
undergoing venoplasty are reported in table 1. The 
frequency of grades 1-3 of facial swelling observed 
at baseline in 60.0% of the patients decreased after 
the intervention and reached 15% after 12 months. 
The median grade of facial swelling significantly 
decreased in the follow-up (P<0.001). The 
frequency increase in grade 0 from 40% to 85% 
(P=0.005), the decrease in grade 2 from 5% to 0% 
(P=0.008) and the decrease in grade 3 from 3% to 
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0% (P=0.022) were statistically significant. 
Similarly, significant decreases (P<0.001) were 
observed in all grades of extremity edema from 
55% to 10% after 12 months of the follow-up 
compared to before the follow-up. Grades 1-3 of 
facial swelling at baseline associated with SVC 
stenosis decreased in all the patients after the 
intervention and reached 25% after one month of 
the follow-up, 30% after six months and 15% after 
12 months. The median grade of SVC stenosis also 
significantly decreased from 1.5 to zero during the 
follow-up (P<0.001), and the frequency increase in 
grade 0 from 0% to 85% (P<0.001) and the 
decrease in grades 1-3 were statistically significant 
(P<0.05) (table 1). The decreases in the frequency 
of facial discomfort from 20% at baseline to 0% one 
month after the intervention, 5% six months after 
and 0% twelve months after were statistically 
insignificant (P=0.129). The decreases in the 
frequency of AVF dysfunction from 20% at baseline 
to 5% one month after the intervention, 0% six 
months after and 0% twelve months after were 
statistically significant (P=0.007). The frequency of 
impairment in dialysis also significantly decreased 
from 13 (65%) at baseline to 5% during the follow-
up (P<0.001) (table 1).  
DISCUSSION 
Quick and effective alleviation of the symptoms 
rather than a long-term recovery constitutes the 
main objective of treating SVC syndrome. 
Conventionally, most patients with SVC syndrome 
associated with malignant diseases have been 
treated with either or both radiation therapy and 
chemotherapy. Venous congestion and partial 
remission normally do not disappear sooner than 
3-7 days of performing radiation therapy. 
Satisfactory responses can be observed in 
approximately 46%-70% of the patients during the 
first two weeks. Steroids and anticoagulant therapy 
are also used in this regard. Endovascular stents 
have been successfully used recently to relieve the 
symptoms. Rapid and sustained therapeutic 
responses were reported in 75%-95% of the 
patients (9-10). Managing the benign causes 
associated with intravascular devices include 
removing the device, thrombolytic therapy, anti-
coagulant administration, endovascular stenting, 
conservative management or a combination of 
these measures (11-12). 
Kee et al. reported benign diseases in 13 out of 51 
patients undergoing stenting, primary clinical 
patency in 10 (77%) out of the 13 and secondary 
Table 1: Clinical symptoms at baseline and follow-up in the patients undergoing venoplasty 
Variable Baseline 1st month 6th month 12th month P-value* 
Facial swelling 
Grade 0 (%) 
Grade 1 (%) 
Grade 2 (%) 
Grade 3 (%) 
Mean (SD) 
Median (IQR) 
 
8 (40.0) 
4 (20.0) 
5 (25.0) 
3 (15.0) 
1.2 (1.1) 
1.0 (2.0) 
 
16 (80.0) 
2 (10.0) 
1 (5.0) 
1 (5.0) 
0.35 (0.81) 
0.0 (0.0) 
 
15 (75.0) 
4 (20.0) 
1 (5.0) 
0 (0.0) 
0.30 (0.57) 
0.0 (0.75) 
 
17 (85.0) 
3 (15.0) 
0 (0.0) 
0 (0.0) 
0.15 (0.37) 
0.0 (0.0) 
 
8.05 (0.005) 
0.02 (0.892) 
7.04 (0.008) 
5.26 (0.022) 
 
23.20 (<0.001) 
Extremity edema 
Grade 0 (%) 
Grade 1 (%) 
Grade 2 (%) 
Grade 3 (%) 
Mean (SD) 
Median (IQR) 
 
9 (45.0) 
2 (10.0) 
6 (30.0) 
3 (15.0) 
1.2 (1.2) 
1.0 (2.0) 
 
16 (80.0) 
2 (10.0) 
1 (5.0) 
1 (5.0) 
0.35 (0.81) 
0.0 (0.0) 
 
16 (80.0) 
3 (15.0) 
1 (5.0) 
0 (0.0) 
0.25 (0.55) 
0.0 (0.0) 
 
18 (90.0) 
2 (10.0) 
0 (0.0) 
0 (0.0) 
0.10 (0.31) 
0.0 (0.0) 
 
9.41 (0.002) 
0.03 (0.874) 
9.00 (0.003) 
5.26 (0.022) 
 
25.38 (<0.001) 
SVC stenosis 
Grade 0 (%) 
Grade 1 (%) 
Grade 2 (%) 
Grade 3 (%) 
Mean (SD) 
Median (IQR) 
 
0 (0.0) 
10 (50.0) 
7 (35.0) 
3 (15.0) 
1.7 (0.75) 
1.5 (1.0) 
 
15 (75.0) 
3 (15.0) 
2 (10.0) 
0 (0.0) 
0.45 (0.94) 
0.0 (0.75) 
 
14 (70.0) 
4 (20.0) 
2 (10.0) 
0 (0.0) 
0.40 (0.68) 
0.0 (1.0) 
 
17 (85.0) 
3 (15.0) 
0 (0.0) 
0 (0.0) 
0.15 (0.37) 
0.0 (0.0) 
 
25.58 (<0.001) 
5.33 (0.021) 
9.30 (0.002) 
5.61 (0.018) 
 
42.82 (<0.001) 
Facial discomfort 
Negative (%) 
Positive (%) 
 
16 (80.0) 
4 (20.0) 
 
20 (100) 
0 (0.0) 
 
19 (95.0) 
1 (5.0) 
 
19 (95.0) 
1 (5.0) 
 
2.31 (0.129) 
AVF dysfunction 
Negative (%) 
Positive (%) 
 
16 (80.0) 
4 (20.0) 
 
19 (95.0) 
1 (5.0) 
 
20 (100) 
0 (0.0) 
 
20 (100) 
0 (0.0) 
 
7.21 (0.007) 
Dialysis impairment  
Negative (%) 
Positive (%) 
 
7 (35.0) 
13 (65.0) 
 
17 (85.0) 
3 (15.0) 
 
19 (95.0) 
1 (5.0) 
 
19 (95.0) 
1 (5.0) 
20.70 (<0.001) 
SVC: superior vena cava; AVF: arteriovenous fistula 
*The p-values calculated using Chi-square test 
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clinical patency in 11 (85%) during a 1-27 month 
follow-up with a median duration of 17 months. 
Moreover, four patients did not return for the 
follow-up. They also reported periprocedural 
mortality and morbidity respectively as 3% and 
10%, and found catheter-directed thrombolysis 
and endovascular stenting to be safe and effective 
treatments for SVC syndrome (13). Lanciego et al. 
found Wallstent vascular endoprosthesis to be an 
early effective treatment in lowering the morbidity 
and complications and relieving the symptoms of 
SVC syndrome from neoplastic origin. Wallstent 
endoprosthesis was therefore proposed as the first 
choice for managing SVC syndrome (14). Kalra et 
al. found endovascular treatment to be effective in 
the short term, and reported the need for repeated 
interventions. They reported that this procedure 
had no negative effects on future surgical 
reconstruction, which made it a rational and 
primary intervention in the selected patients. The 
patients who failed to respond to endovascular 
treatment were also identified as candidates for 
open surgical reconstruction (15). Despite 
reporting the same clinical and technical success as 
that of unilateral Wallstent placement, Dinkel et al. 
found bilateral Wallstent placement to be 
associated with a lower patency and more 
complications (16). Given the immediate and 
relatively stable relief of the symptoms caused by 
endovascular stenting, Kim et al. found this 
technique to be the first choice of treating and 
alleviating the symptoms of SVC syndrome (9). In 
2018, Hooker et al. found both surgical and 
endovascular treatments to often require 
secondary interventions for maintaining patency, 
and percutaneous treatment to be associated with 
fewer sequelas. They also found the treatment of 
benign SVC syndrome to be a safe, effective and 
reasonable primary method (18). Given the high 
risks of the surgical correction of SVC syndrome, 
the focus has shifted to endovascular management 
over the past few decades. In the US, uncovered 
balloon-expandable stents, including Z stents, 
Palmaz stents and Wallstent® (Boston Scientific), 
are the main stents in use. The typical 
complications of SVC stenting include thrombosis, 
stent migration, hemopericardium and transient 
chest pain. Using uncovered stents or covered 
stents with uncovered margins has lowered the 
incidence of stent migration. In case SVC stenosis is 
at the confluence of the 2 veins, covered stents are 
yet associated with higher risks of stent migration 
and obstruction of unilateral azygos and 
brachiocephalic veins (19-20). Gustavo found 
stents to be transiently beneficial for most patients 
with peripheral or central upper-extremity 
symptomatic venous obstruction. Re-interventions 
and regular follow-up were required for 
maintaining patency and clinical success. The 
clinical success of the stents used for central 
venous lesions is lower than that of the stents used 
for peripheral venous lesions (21). The objectives 
of treating malignant SVC-related syndromes 
include alleviating the symptoms and treating the 
underlying diseases. Successfully managing the 
underlying etiology depends on the type and 
degree of spread of the disease and the overall 
prognosis, which is tightly related to the histology 
and whether or not previous treatments have been 
performed. All these factors affect the selection of 
treatment methods. A major finding of the present 
study was that recurrence was more frequent in 
the cases whose venoplasty was not optimal. 
Stenting during the follow up was also associated 
with lower recurrence rates, especially in the cases 
with suboptimal results. Given the risk of 
recurrence, optimal results are recommended that 
be obtained by closely observing the patients and 
taking diagnostic and therapeutic measures in case 
of a significant clinical suspicion. 
Imaging techniques play a key role in diagnosing 
and treating different conditions that affect SVC. 
Indirect radiographic symptoms of the chest, 
including mediastinal widening and mediastinal 
masses, can suggest malignancy arising from the 
lung, pleura or trachea. These radiographs can also 
be used to evaluate the position of central venous 
catheters in certain benign cases. CT scans and MRI 
can also be used to show the level and extent of 
venous obstruction, map the route of venous 
drainage and identify the underlying etiology. 
Venography is normally required as part of 
interventions for acute thrombotic SVC syndrome 
to evaluate the location and extent of SVC 
obstruction and collateral drainage (5-7). 
Limitations  
Due to low prevalence of SVC syndrome conducting 
clinical trial has considerable difficulties and most 
of performed surveys have same methods. 
Therefore, the results cannot be generalized with 
proper confidence and still need to be assessed. 
CONCLUSIONS 
Findings of the present study revealed the 
appropriate patency rate of endovascular 
treatment in patients with SVC syndrome in 
presence of central venous catheter. 
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